Top Page
Futura Medical
(LSE:FUM)
Futura Medical (FUM) vs. iShares MSCI United Kingdom ETF (EWC)
Futura Medical Business Overview & Revenue Model
Futura Medical Earnings Call Summary
Futura Medical Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.93M | 3.10M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.57M | 1.77M | -24.73K | -19.81K | -25.01K |
| EBITDA | 1.41M | -6.83M | -6.85M | -5.85M | -2.90M |
| Net Income | 1.29M | -6.51M | -5.85M | -4.96M | -2.41M |
Balance Sheet | |||||
| Total Assets | 13.59M | 11.82M | 6.47M | 11.80M | 1.62M |
| Cash, Cash Equivalents and Short-Term Investments | 6.60M | 7.71M | 4.03M | 10.37M | 1.02M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.63M | 6.34M | 1.75M | 2.08M | 766.52K |
| Stockholders Equity | 8.96M | 5.48M | 4.72M | 9.72M | 853.54K |
Cash Flow | |||||
| Free Cash Flow | -1.29M | -935.60K | -6.52M | -4.29M | -4.55M |
| Operating Cash Flow | 438.41K | 570.25K | -5.78M | -3.87M | -4.54M |
| Investing Cash Flow | -1.73M | -1.43M | -740.70K | -419.72K | -7.45K |
| Financing Cash Flow | 170.91K | 4.55M | 169.58K | 13.65M | 3.06M |
Futura Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £32.47M | -3.89 | -204.29% | ― | 3.31% | 21.91% | |
52 Neutral | £7.59M | -0.63 | -115.97% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £55.64M | -65.15 | -11.24% | ― | 283.74% | 78.57% | |
49 Neutral | £30.33M | -3.82 | -46.84% | ― | ― | ― | |
43 Neutral | £6.09M | -42.14 | -2.42% | ― | ― | ― | |
42 Neutral | £266.56M | ― | ― | ― | ― | ― |
Futura Medical Corporate Events
Futura Medical has confirmed that its total issued share capital stands at 581,327,755 ordinary shares, all of which carry voting rights as the company holds no shares in treasury. This updated share capital and voting rights figure provides a new denominator for investors assessing whether they must disclose holdings or changes in their stake under UK financial disclosure and transparency rules, reinforcing governance clarity and regulatory compliance for shareholders and market participants.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Futura Medical has received a notice of allowance for its patent for Eroxon® in China, providing protection until 2040. This development represents a significant commercial opportunity given the high prevalence of erectile dysfunction among adult males in China. The patent enhances Futura’s competitive position and supports its commercial strategy as the company seeks partners in the Chinese market. The allowance adds to Futura’s existing intellectual property protection in Europe, Hong Kong, Taiwan, and the US, with further applications pending in additional markets.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Futura Medical plc announced that its directors and associated persons have subscribed for 6,000,000 new ordinary shares as part of a recent fundraising initiative. This move signifies strong internal confidence in the company’s growth prospects and aims to bolster its financial position to further develop and commercialize its innovative sexual health products, potentially strengthening its market position and delivering value to stakeholders.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Futura Medical announced a board change as Harmesh Suniara steps down as Non-Executive Director following a reduction in Lombard Odier Asset Management’s shareholding. This change comes after a successful fundraising, which provides the company with a stable financial footing. Futura is now focused on completing a strategic review and advancing the development of its products, Eroxon Intense and WSD4000, which could significantly impact the sexual health market.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Futura Medical announced a board change with Harmesh Suniara stepping down as Non-Executive Director following a significant reduction in Lombard Odier Asset Management’s shareholding. The company, having secured a strong financial position through recent fundraising, is now concentrating on completing a strategic review and advancing its product development efforts, particularly Eroxon Intense and WSD4000, to strengthen its market position.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Futura Medical plc announced that Lombard Odier Asset Management, associated with Non-Executive Director Harmesh Suniara, sold 4,441,678 ordinary shares in the company. This transaction reduces Lombard Odier’s holding to 26.90% of Futura’s issued share capital. The sale may impact the company’s market perception and stakeholder confidence, as it involves a significant shareholder reducing its stake.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Futura Medical has announced the dispatch of a Circular and Notice of General Meeting to shareholders, following a recent fundraise of £2.75 million. The meeting is scheduled for December 2, 2025, at the company’s registered office in Surrey. This development is part of Futura’s ongoing efforts to strengthen its financial position and enhance its market presence in the sexual health industry, potentially impacting stakeholders positively by addressing unmet needs in the market.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Futura Medical has announced a successful fundraise of £2.75 million through an oversubscribed firm placing and subscription of new ordinary shares. This funding will support the company’s strategic review and development plans for Eroxon® Intense and WSD4000, as well as strengthen its working capital position. The company also announced several board changes, including the appointment of Alex Duggan as permanent CEO. The fundraise is crucial for the company’s operations, as it faces slower than expected sales and limited cash resources, with the potential risk of insolvency if the fundraising resolutions are not passed.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
Futura Medical announced its total issued share capital consists of 306,120,659 Ordinary Shares, with no shares held in treasury. This information is crucial for shareholders to determine their interests in the company under FCA’s Disclosure and Transparency Rules. The announcement reflects Futura’s ongoing commitment to transparency and regulatory compliance, potentially impacting shareholder decisions and market perceptions.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.